• (1S,3R)-RSL3: Precision GPX4 Inhibition and Ferroptosis in C

  2026-05-09

  (1S,3R)-RSL3 is a potent glutathione peroxidase 4 inhibitor and ferroptosis inducer, offering unique advantages for oxidative stress and cancer biology research. This article dives deep into its mechanism, preclinical applications, and protocol optimization, distinguishing itself with new insights from recent glioblastoma research.

• Capsaicin in Experimental Research: TRPV1 and KDM1A Use-Case

  2026-05-08

  Capsaicin (E)-Capsaicin is more than a pungent molecule—its dual action as a TRPV1 activator and a potent, reversible KDM1A/LSD1 inhibitor positions it as a uniquely versatile research tool. This article deciphers advanced workflows, troubleshooting best practices, and the latest insights from peer-reviewed evidence to empower translational and mechanistic studies.

• Escitalopram in Antidepressant Research: Protocols & Pitfall

  2026-05-08

  APExBIO's Escitalopram (Lexapro) empowers precise modeling of serotonergic signaling, enabling reproducible workflows for both antidepressant and anxiolytic activity studies. This in-depth guide delivers actionable protocol enhancements, troubleshooting strategies, and translational insights—anchored in the latest evidence and real-world research experience.

• Early Life Adversity Impairs Defensive Behaviors via Oxytoci

  2026-05-07

  Tan et al. (2026) reveal that social deprivation during early postnatal life disrupts visually evoked innate defensive behaviors in mice by downregulating oxytocin receptor signaling in the superior colliculus. Their mechanistic findings advance our understanding of how early life adversity leads to persistent neural and behavioral alterations, providing a framework for targeted intervention studies.

• Chemotactic Crawling of Vesicles via Multivalent DNA Adhesio

  2026-05-07

  This study establishes a biomimetic system using DNA-functionalized vesicles to directly investigate chemotactic crawling driven by multivalent adhesion along ligand-density gradients. The findings clarify how binding strength and vesicle size determine motion, informing the design of synthetic motile systems and offering methodological insights for molecular biology researchers.

• Berberrubine Inhibits Thrombosis via the Vitamin K Cycle in

  2026-05-06

  This study demonstrates that berberrubine, a primary metabolite of berberine, inhibits thrombus formation in mice by modulating the vitamin K catalytic cycle. By integrating metabolomics and molecular docking, the authors reveal berberrubine's unique mechanism of action and highlight its potential for safer antithrombotic drug development.

• Reliable Mitochondrial Analysis with JC-1 Mitochondrial Memb

  2026-05-06

  This article addresses key laboratory challenges in cell apoptosis detection and mitochondrial function analysis, illustrating how the JC-1 Mitochondrial Membrane Potential Assay Kit (SKU K2002) delivers reproducible, quantitative results. Scenario-driven Q&A blocks offer practical guidance, evidence-backed protocol parameters, and candid vendor selection insights. Researchers will find actionable solutions to improve assay reliability and workflow confidence using SKU K2002.

• AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic R

  2026-05-05

  AZ505 is a substrate-competitive SMYD2 inhibitor with nanomolar potency, supporting advanced epigenetic regulation and cancer biology research. Its selectivity, validated by peer-reviewed studies, enables precise interrogation of SMYD2-dependent methylation in disease models including fibrosis and cancer.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati

  2026-05-05

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) from APExBIO empowers researchers with reliable, broad-spectrum protection of protein phosphorylation states, critical for accurate signaling pathway and phosphoproteomic studies. This guide translates cutting-edge cardiac remodeling research and real-world workflows into actionable protocols, troubleshooting strategies, and advanced use-cases for high-fidelity experimental outcomes.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-05-04

  This study demonstrates that increasing GLT-1 expression in astrocytes reduces neuronal apoptosis and cognitive dysfunction following traumatic brain injury (TBI) by suppressing the CB1-CREB signaling pathway. These findings highlight a mechanistic link between endocannabinoid signaling, glutamate transport, and neuroprotection, informing future strategies for memory impairment research and therapeutic development.

• Adefovir (GS-0393): Pharmacokinetics, OAT1 Probing, and Next

  2026-05-04

  Explore the advanced pharmacokinetic modeling and OAT1 transporter specificity of Adefovir (GS-0393), a cornerstone HBV antiviral agent. This article unveils fresh insights for experimental design, building on and extending current benchmarks in hepatitis B virus research.

• Laminin (925-933): Protocol Parameters and Workflow Guidance

  2026-05-03

  Laminin (925-933), a synthetic peptide from the laminin B1 chain, enables defined modulation of cell adhesion and migration in in vitro assays. It is best applied in mechanistic studies of cell attachment, chemotaxis, and metastatic potential, but is not recommended for diagnostic or direct therapeutic use. This guide outlines actionable parameters and workflow safeguards to ensure reproducible results.

• EPZ-6438 in Precision Epigenetics: Mechanistic Insight and A

  2026-05-02

  Explore the scientific depth of EPZ-6438, a potent EZH2 inhibitor, with a focus on its mechanistic impact and advanced assay design in epigenetic cancer research. This article uniquely integrates evidence from recent studies and practical assay considerations.

• (S)-Mephenytoin and CYP2C19: Quantitative Assay Design in Or

  2026-05-01

  (S)-Mephenytoin is a pivotal CYP2C19 substrate for interrogating cytochrome P450 metabolism in cutting-edge pharmacokinetic models. This article provides a quantitative, protocol-driven roadmap—uniquely bridging kinetic assay optimization and human iPSC-derived organoid systems—to enable translational research advances beyond current gold-standard discussions.

• VE-822 ATR Inhibitor: Mechanisms and Benchmarks in Cancer Re

  2026-05-01

  VE-822 is a highly potent and selective ATR inhibitor used to disrupt DNA damage response (DDR) in cancer models. It sensitizes pancreatic ductal adenocarcinoma (PDAC) cells to chemoradiotherapy without increasing normal tissue toxicity. This article details VE-822’s mechanism, evidence, and practical applications for translational oncology workflows.

16190 records 1/1080 page Next 12345 下5页 Last page